Salivary Gland Cancers Clinical Trial
Official title:
Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
To learn if sacituzumab govitecan can help to control salivary gland cancer.
Primary Objectives: - To assess the efficacy of SG in patients with R/M secretory gland carcinomas, specifically ACC (cohort 1) and SDC, adeno-NOS, and MEC (cohort 2) Secondary Objectives: - To estimate the median duration of response (DOR) - To estimate the median progression-free survival (PFS) - To estimate the median overall survival (OS) - To assess safety of SG Tertiary / Exploratory Objectives: - To explore biomarkers that may predict response to therapy ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01678105 -
A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
|
Phase 2 | |
| Active, not recruiting |
NCT02568267 -
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
|
Phase 2 | |
| Completed |
NCT02857712 -
Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14
|
Phase 2 |